| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The present study was undertaken to determine whether a non-peptide arginine vasopressin (AVP) antagonist (5-dimethylamino - 1- [4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepine; OPC-31260) antagonizes the antidiuretic action of endogenous and exogenous AVP in conscious rats. OPC-31260, given orally at a dose of 5 mg/kg or higher, increased urinary volume (UV) and reduced urinary osmolality (Uosm) in a dose-dependent manner, in rats acutely denied access to water. Minimal Uosm was obtained 1–2 h after oral administration of OPC-31260. OPC-31260 caused sustained water diuresis for more than 12 h when water was available ad libitum since OPC-31260 (30 mg/kg) reduced Uosm to less than 230 mOsmol/kg H2O, significantly less than the control value of 600 mOsmol/kg H2O. Water deprivation for 24 h increased plasma AVP levels to 7·2 pmol/l and increased Uosm to 2160 mOsmol/kg H2O. In such water-deprived rats, oral administration of OPC-31260 at 100 mg/kg was diuretic; it markedly increased free water clearance and decreased Uosm to 202 mOsmol/kg H2O.
In homozygous Brattleboro rats (with inherited AVP deficiency), given free access to water, subcutaneous infusion of the V2 agonist 1-deamino-8-D-AVP (dDAVP) at a rate of 1 ng/h markedly decreased UV to 12.6 from 148·7 ml/day and increased Uosm to 1762 from 231 mOsmol/kg H2O. OPC-31260 (30 mg/kg) promptly increased UV and reduced Uosm to levels similar to those before the administration of dDAVP; repeated OPC-31260 treatment had sustained effects. These results indicate that OPC-31260 is an orally effective non-peptide AVP antagonist to the antidiuretic action of AVP in the conscious rat.
Journal of Endocrinology (1994) 143, 227–234
This article has been cited by other articles:
|
|
 |
|
  J. Perucca, D. G. Bichet, P. Bardoux, N. Bouby, and L. Bankir Sodium Excretion in Response to Vasopressin and Selective Vasopressin Receptor Antagonists J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1721 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. M. Lam, B. C. B. Ko, S. Tam, R. Morris, J. Y. Yang, S. K. Chung, and S. S. M. Chung Osmotic Response Element-binding Protein (OREBP) Is an Essential Regulator of the Urine Concentrating Mechanism J. Biol. Chem., November 12, 2004; 279(46): 48048 - 48054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Wong and J. G. Verbalis Vasopressin V2 receptor antagonists Cardiovasc Res, August 15, 2001; 51(3): 391 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Palm and P. Gross V2-vasopressin receptor antagonistsmechanism of effect and clinical implications in hyponatraemia Nephrol. Dial. Transplant., November 1, 1999; 14(11): 2559 - 2562. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Marples, B. M. Christensen, J. Frokiaer, M. A. Knepper, and S. Nielsen Dehydration reverses vasopressin antagonist-induced diuresis and aquaporin-2 downregulation in rats Am J Physiol Renal Physiol, September 1, 1998; 275(3): F400 - F409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Burrell, P. A. Phillips, J. Risvanis, R. K. Chan, K. L. Aldred, and C. I. Johnston Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat Am J Physiol Heart Circ Physiol, July 1, 1998; 275(1): H176 - H182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Saito, S.-e Ishikawa, K. Abe, K. Kamoi, K. Yamada, K. Shimizu, T. Saruta, and S. Yoshida Acute Aquaresis by the Nonpeptide Arginine Vasopressin (AVP) Antagonist OPC-31260 Improves Hyponatremia in Patients with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH) J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1054 - 1057. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
